Does cardamom lower blood pressure and inflammation?

Cardamom (Elettaria cardamomum) contains two main categories of active compounds. The volatile essential oil — dominated by 1,8-cineole (eucalyptol), alpha-terpinyl acetate, and linalool — gives it the distinctive aromatic quality and accounts for much of its antimicrobial and digestive activity. The non-volatile fraction contains flavonoids including quercetin, kaempferol, and luteolin, along with phenolic acids and terpenes that drive the cardiovascular and anti-inflammatory effects.

Blood pressure reduction is the best-documented benefit. A 2024 meta-analysis of randomized clinical trials found that cardamom supplementation significantly reduced both systolic and diastolic blood pressure as well as key inflammatory markers including hs-CRP, IL-6, and TNF-alpha¹. An earlier meta-analysis focused specifically on metabolic syndrome patients found significant reductions in diastolic blood pressure (average -0.91 mmHg) and C-reactive protein². The mechanism involves cardamom's compounds stimulating nitric oxide synthesis and relaxing smooth muscle in blood vessel walls — the same pathway through which many antihypertensive drugs work. Cardamom also enhances fibrinolytic activity (the breakdown of blood clots), which adds a separate cardiovascular protective mechanism³.

Inflammation reduction is mechanistically tied to cardamom's flavonoid content, which inhibits NF-kB, the master switch controlling inflammatory gene expression. Clinical studies consistently show reductions in hs-CRP, a blood marker for systemic inflammation, with 3 g/day over 8-12 weeks.

Liver and metabolic health: A double-blind RCT in overweight patients with non-alcoholic fatty liver disease (NAFLD) found that green cardamom supplementation (3 g/day for 3 months) significantly increased Sirtuin-1 (a longevity-associated protein involved in fat metabolism) and reduced liver enzymes (ALT), inflammation markers, and body weight compared to placebo⁴. This is particularly relevant given how common NAFLD has become alongside metabolic syndrome.

Digestive support: Cardamom has historically been used as a digestive aid, and its volatile oil compounds are now understood to stimulate digestive enzyme secretion, relax intestinal smooth muscle (reducing cramping), and exert antimicrobial effects against gut pathogens including H. pylori. It is often combined with ginger or fennel in traditional digestive formulas.

Emerging cancer research: Preclinical studies show that cardamom compounds, particularly 1,8-cineole and quercetin, inhibit cancer cell proliferation and sensitize tumors to chemotherapy through multiple pathways. Human clinical evidence is preliminary, but the mechanistic rationale is substantial⁵.

Practical use: Ground cardamom powder is the most studied form. Add to coffee (it's a traditional pairing in Arabic and Scandinavian coffee culture), oatmeal, smoothies, curries, and baked goods. Whole pods can be cracked and steeped in tea or rice. For therapeutic effects, aim for 1-3 g daily (roughly 1/4 to 3/4 teaspoon). Both green cardamom (Elettaria cardamomum) and black cardamom (Amomum subulatum) are used culinarily, but most research has focused on green cardamom.

Cross-reference: See our ginger and turmeric pages for other culinary spices with robust anti-inflammatory evidence.

Heydarian et al. (2024) — Meta-analysis of cardamom on inflammation and blood pressure¹

This systematic review and meta-analysis in Food Science & Nutrition pooled data from randomized clinical trials examining cardamom's effects on inflammatory markers and blood pressure in adults. The analysis found statistically significant reductions in hs-CRP, interleukin-6, TNF-alpha, systolic blood pressure, and diastolic blood pressure compared to placebo. The blood pressure reductions, while modest in absolute terms, are clinically meaningful given that even small chronic reductions at a population level translate to substantially fewer cardiovascular events. The consistency of effect across multiple inflammatory biomarkers is notable, suggesting cardamom acts upstream on inflammatory signaling rather than suppressing individual pathways.

Izadi et al. (2023) — Green cardamom and metabolic syndrome²

This Phytotherapy Research meta-analysis focused specifically on patients with metabolic syndrome and related disorders, analyzing eight randomized controlled trials involving 595 participants (299 intervention, 296 placebo). Key findings: diastolic blood pressure reduced by a weighted mean difference of -0.91 mmHg (95% CI: -1.19 to -0.62, p<0.001); hs-CRP reduced by -1.21 mg/L (95% CI: -2.18 to -0.24, p=0.013); IL-6 reduced by -2.41 ng/L (95% CI: -4.35 to -0.47, p=0.015). The effect on systolic blood pressure did not reach significance. The authors noted that dose and duration varied across studies, which may partly explain heterogeneity, and called for standardized protocols in future trials.

Verma, Jain, and Katewa (2009) — Clinical study on blood pressure and fibrinolysis³

This early clinical trial administered 3 g/day cardamom powder to participants with stage 1 hypertension for 12 weeks. Results showed significant reductions in systolic, diastolic, and mean blood pressure (p<0.001). Fibrinolytic activity increased by approximately 11%, and total antioxidant status improved significantly. Participants also reported better feelings of well-being. This remains one of the most-cited human studies demonstrating cardamom's direct antihypertensive action, and established the 3 g/day dose that subsequent research has used.

Daneshi-Maskooni et al. (2018) — Cardamom in NAFLD⁴

This double-blind RCT enrolled 87 overweight or obese patients with confirmed non-alcoholic fatty liver disease, randomizing them to 1 g cardamom three times daily (2 × 500 mg capsules per meal) or matched placebo for three months. The cardamom group showed significant increases in Sirtuin-1 (Sirt1), a NAD+-dependent deacetylase involved in fat metabolism and cellular energy sensing, alongside significant reductions in ALT (a liver damage marker), TNF-alpha, and IL-6. Body weight also decreased significantly compared to placebo. This study is particularly relevant given the NAFLD epidemic accompanying rising rates of metabolic syndrome. The Sirt1 upregulation is mechanistically interesting — Sirt1 promotes fatty acid oxidation and reduces hepatic lipid accumulation, offering a potential explanation for the liver enzyme improvements.

Strength of evidence assessment: Cardamom's blood pressure and anti-inflammatory effects are supported by multiple randomized controlled trials and two meta-analyses, which is a reasonably strong evidence base for a dietary spice. The primary limitation is that individual trials tend to be small (typically 40-100 participants) and use heterogeneous dosing. The NAFLD study adds a compelling mechanistic angle through Sirt1 measurement. The typical research dose of 3 g/day is achievable through diet and is safe with no significant adverse effects reported across trials.